Related Experiment Videos
The isolated working heart model in infarcted rat hearts
G Itter1, W Jung, B A Schoelkens
1Aventis Pharma Deutschland, LASW (H840), Zi. 140, DG Cardiovascular Diseases, D-65926 Frankfurt/ Main, Germany. Gabi.Itter@aventis.com
Laboratory Animals
|May 20, 2005
Summary
A new working heart model in rats with congestive heart failure (CHF) effectively mimics end-stage heart failure symptoms. This validated model aids in testing new therapies for heart failure patients.
Area of Science:
- Cardiology
- Physiology
- Animal Models
Background:
- Congestive heart failure (CHF) is a leading cause of death in Western countries.
- Current treatments for heart failure are largely palliative.
- Developing predictive animal models is crucial for advancing heart failure research.
Purpose of the Study:
- To establish and validate a working heart model in rats with induced congestive heart failure (CHF).
- To evaluate cardiodynamics and geometric properties of the left ventricle in this model.
- To adapt existing formulae for accurate parameter determination in infarcted rat hearts.
Main Methods:
- Congestive heart failure (CHF) was induced in Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR) via permanent left coronary artery occlusion.
- The 'working heart' model was utilized to assess cardiodynamics, including contractility.
- Left ventricular geometric properties were measured using planimetry (stereology).
Main Results:
- The spontaneously hypertensive rat (SHR) model exhibited characteristic CHF parameters and symptoms (NYHA III-IV) 8-12 weeks post-myocardial infarction (MI).
- SHR rats displayed severe clinical signs of CHF, including dyspnea and edema, and pathological findings like pulmonary edema and ventricular dilation.
- The working heart model revealed reduced heart power and contractility in infarcted rats, particularly in SHR compared to WKY rats.
Conclusions:
- The established working heart model in SHR rats with myocardial infarction (MI) accurately replicates end-stage CHF.
- This validated model provides a valuable platform for the early testing of novel therapeutic strategies for CHF.
- Further research using this model can accelerate the development of causal therapies for heart failure.